Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Bifidobacterium longum BB536 and Increased Neutrophil Phagocytic Activity

Doses used in studies

CFU/day: 100 billion (median 100 billion, IQR 100 billion–100 billion) — 1 study

Time to effect

Median: 3.3 months · IQR 3.3 months–3.3 months · Range 3.3 months–3.3 months — Reported in 1 of 1 study

1 of 1 paper

Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly.
- 2010-05-23
- RCT
- Bioscience, biotechnology, and biochemistry 74(5)
- - Kazuyoshi Namba
  - Michiko Hatano
  - Tomoko Yaeshima
  - Mitsunori Takase
  - Kunihiko Suzuki
- PubMed: 20460726
- DOI: 10.1271/bbb.90749
5 Insights on
- Increased Neutrophil Phagocytic Activity
- High evidence
- Elderly
neutrophil phagocytic activity and NK cell activity tended to maintain slightly higher levels in the BB536 group than in the placebo group.
Effect
Neutral
Effect size
Small
Significant
No
Dose
1 x 10^11 CFU daily